anti yfv ns1 antibody  (Native Antigen Inc)

Journal: Vaccines

Article Title: A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses

doi: 10.3390/vaccines9121492

Figure Lengend Snippet: Humoral immune responses in mice, immunized with YF-replicons. ( A ) Schematic representation of the experimental design. ( B – D ) YFV-NS1-specific, ( E , F ) MERS-CoV S1-specific and ( G ) SARS-CoV S1-specific IgG antibodies, as measured by ELISA and expressed as endpoint titers. ( H – J ) Neutralizing titers against MERS-CoV ( H , I ) and against mouse-adapted SARS-CoV strain MA15 and a human-derived SARS-CoV strain Fr-1 ( J ) as measured by virus neutralization test and expressed as endpoint titers. The dotted lines indicate the lowest detectable titer (detection limit of the assay). All symbols represent individual titer values, and the geometric means are shown with horizontal lines. The YF-replicon used as a vaccine is shown above each graph. Statistical analysis was performed with nonparametric ANOVA ( B – D ) and with a t -test ( E , F , H – J ). Differences with p values ≤ 0.05 were considered significant and are shown where relevant. On the x-axis, days post-prime vaccination are shown.

Article Snippet: Mouse anti-YFV-NS1 monoclonal antibody (BioFront Technologies, Tallahassee, FL, USA, BF-087) was used as a positive control for the YFV NS1-based ELISA, while SARS-CoV hyperimmune serum kindly provided by Dr. Bart Haagmans (Erasmus MC, Rotterdam, The Netherlands) was used as a positive control for the SARS S1-based ELISA.

Techniques: Enzyme-linked Immunosorbent Assay, Derivative Assay, Virus, Neutralization